Cold Atmospheric Plasma Treatment of Chondrosarcoma Cells Affects Proliferation and Cell Membrane Permeability.
chondrosarcoma
cold atmospheric plasma
growth inhibition
membrane functionality
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
26 Mar 2020
26 Mar 2020
Historique:
received:
28
02
2020
revised:
17
03
2020
accepted:
24
03
2020
entrez:
1
4
2020
pubmed:
1
4
2020
medline:
17
12
2020
Statut:
epublish
Résumé
Chondrosarcoma is the second most common malign bone tumor in adults. Surgical resection of the tumor is recommended because of its resistance to clinical treatment such as chemotherapy and radiation therapy. Thus, the prognosis for patients mainly depends on sufficient surgical resection. Due to this, research on alternative therapies is needed. Cold atmospheric plasma (CAP) is an ionized gas that contains various reactive species. Previous studies have shown an anti-oncogenic potential of CAP on different cancer cell types. The current study examined the effects of treatment with CAP on two chondrosarcoma cell lines (CAL-78, SW1353). Through proliferation assay, the cell growth after CAP-treatment was determined. A strong antiproliferative effect for both cell lines was detected. By fluorescein diacetate (FDA) assay and ATP release assay, alterations in the cell membrane and associated translocation of low molecular weight particles through the cytoplasmic membrane were observed. In supernatant, the non-membrane-permeable FDA and endogenously synthesized ATP detected suggest an increased membrane permeability after CAP treatment. Similar results were shown by the dextran-uptake assay. Furthermore, fluorescence microscopic G-/F-actin assay was performed. G- and F-actin were selectively dyed, and the ratio was measured. The presented results indicate CAP-induced changes in cell membrane function and possible alterations in actin-cytoskeleton, which may contribute to the antiproliferative effects of CAP.
Identifiants
pubmed: 32225067
pii: ijms21072291
doi: 10.3390/ijms21072291
pmc: PMC7177321
pii:
doi:
Substances chimiques
Actins
0
Plasma Gases
0
Adenosine Triphosphate
8L70Q75FXE
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Oncologist. 2008 Mar;13(3):320-9
pubmed: 18378543
Oncoimmunology. 2014 Dec 13;3(9):e955691
pubmed: 25941621
J Cell Biochem Suppl. 1995;22:24-32
pubmed: 8538205
Clin Orthop Relat Res. 2007 Oct;463:166-72
pubmed: 17632422
PLoS One. 2015 Jul 01;10(7):e0130350
pubmed: 26132846
Cell Death Dis. 2018 Dec 5;9(12):1179
pubmed: 30518936
Sci Rep. 2018 Oct 18;8(1):15418
pubmed: 30337623
Cancers (Basel). 2020 Jan 17;12(1):
pubmed: 31963398
Oxid Med Cell Longev. 2019 Oct 8;2019:9062098
pubmed: 31687089
Crit Rev Food Sci Nutr. 2018;58(15):2583-2597
pubmed: 28613926
Oxid Med Cell Longev. 2019 Jan 13;2019:7017363
pubmed: 30733851
Anticancer Agents Med Chem. 2018;18(6):824-831
pubmed: 29732979
Hematol Oncol Clin North Am. 2013 Oct;27(5):1021-48
pubmed: 24093174
PLoS One. 2011 Jan 21;6(1):e16270
pubmed: 21283714
CA Cancer J Clin. 2006 Nov-Dec;56(6):366-75
pubmed: 17135693
Cancer. 1998 Nov 15;83(10):2105-19
pubmed: 9827715
Int J Oncol. 2002 Jul;21(1):165-70
pubmed: 12063564
Anticancer Res. 2016 Nov;36(11):5915-5922
pubmed: 27793916
Anticancer Res. 2020 Feb;40(2):841-846
pubmed: 32014927
PLoS One. 2011;6(11):e28154
pubmed: 22140530
Curr Opin Oncol. 2007 Jul;19(4):371-6
pubmed: 17545802
Biomed Res Int. 2015;2015:506059
pubmed: 26539504
Anticancer Res. 2017 Mar;37(3):1031-1038
pubmed: 28314261
J Bone Joint Surg Br. 2002 Jan;84(1):93-9
pubmed: 11837841
Anticancer Res. 2019 Jan;39(1):151-157
pubmed: 30591452
J Orthop Res. 1999 Nov;17(6):935-40
pubmed: 10632461
Anticancer Agents Med Chem. 2018;18(6):805-814
pubmed: 29623855
In Vivo. 2019 Jul-Aug;33(4):1011-1026
pubmed: 31280189
Redox Biol. 2020 Feb;30:101423
pubmed: 31931281
Antimicrob Agents Chemother. 2011 Mar;55(3):1053-62
pubmed: 21199923
Sci Rep. 2018 Aug 24;8(1):12734
pubmed: 30143716
Free Radic Res. 2010 May;44(5):479-96
pubmed: 20370557
Cancers (Basel). 2020 Jan 02;12(1):
pubmed: 31906595
Oncol Lett. 2020 Jan;19(1):283-290
pubmed: 31897140
Free Radic Res. 2014 May;48(5):542-9
pubmed: 24528134
J Appl Microbiol. 2014 Apr;116(4):784-94
pubmed: 24372804
Br J Cancer. 2011 Oct 25;105(9):1295-301
pubmed: 21979421
Front Microbiol. 2018 Dec 19;9:3164
pubmed: 30619223
Sci Rep. 2019 Jan 24;9(1):634
pubmed: 30679720
F1000Res. 2018 Nov 20;7:
pubmed: 30519452
Cell Death Dis. 2013 May 23;4:e642
pubmed: 23703387
Int J Mol Sci. 2017 May 03;18(5):
pubmed: 28467380
Int J Cancer. 2012 May 1;130(9):2185-94
pubmed: 21702038
Biol Chem. 2018 Dec 19;400(1):19-38
pubmed: 30403650
Oncotarget. 2017 Feb 28;8(9):15977-15995
pubmed: 27845910